Background Impulse‐control and related behavioral disorders (ICBDs) significantly impact
the lives of Parkinson's disease (PD) patients and caregivers, with lasting consequences if …

Parkinson's disease (PD) is the second most common age-related neurodegenerative
disorders of the central nervous system, which mainly impairs the motor system. However …

Background and purpose Impulse control disorders (ICD s) in Parkinson's disease (PD) are
associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical …

Clinicians are well aware of the fact that patients with Parkinson's disease may significantly
deteriorate following a systemic infection or, in its most severe case, may even develop an …

Motor and non-motor symptoms (NMS) have a substantial effect on the health-related quality
of life (QoL) of patients with Parkinson's disease (PD). Transdermal therapy has emerged as …

Introduction Behavioural symptoms are common manifestations of Parkinson's disease and
include depression, anxiety, impulse control disorders, hallucinations, psychosis, and …

Nondopaminergic neurotransmitters such as adenosine, norepinephrine, serotonin,
glutamate, and acetylcholine are all involved in Parkinson's disease (PD) and promote its …

The akinetic crisis is a well-known, rare, potentially life-threatening condition in Parkinson's
disease with subacute worsening of akinesia, rigidity, fever, impaired consciousness …

Dopamine (DA) agonists, as an excellent dopamine replacement therapy for patients with
early and advanced Parkinson's disease (PD), play a vital role in controlling motor and …

Parkinson's disease (PD) is a chronic, progressive condition affecting around 1% of the
population older than 60 years. Upon long-term treatment with levodopa, the mainstay of …